FITC-geldanamycin

Images

 
Product Image: FITC-geldanamycin [NB610-81561] - Chemical structure of Geldanamycin- FITC (NB610-81561), a Hsp90 inhibitor. Molecular Formula: C55H63N5O13S. Molecular Weight: 560.6 g/mol.

Product Details

Summary
Applications PI

Order Details

FITC-geldanamycin Summary

Description
Hsp90 fluorescent probe

Applications/Dilutions

Dilutions
  • Product Image
Application Notes
Purple solid. Soluble in DMSO (>10 mg/mL).

Packaging, Storage & Formulations

Storage
Store at -20C. Avoid freeze-thaw cycles.

Background

Geldanamycin is a benzoquinoid ansamycin produced by Streptomyces hygroscopicus. It binds specifically to heat shock protein HSP90 and downregulates target proteins including tyrosine kinases, steroid receptors, transcription factors and cell cycle regulatory kinases (1, 2). It induces the inactivation, destabilization and eventual degradation of HIF-1 alpha (3). It is also an inhibitor of pp60src tyrosine kinase and of c-myc gene expression in murine lymphoblastoma cells. It inhibits the transforming activity of abl, erbB, fps, src, and yes (4). Geldanamycin is capable of destabilizing several oncogene and proto-oncogene products; it is a potent inhibitor of the nuclear hormone receptor family (5). It protects against alpha-synuclein toxicity to dopaminergic neurons in Drosophila, and destabilizes mutant p53 protein from a number of breast, leukemic, and prostate cell lines (6). Inhibits basal and hypoxia-induced expression of c-Jun (IC50=75 nM) and abolishes hypoxia-induced increase in c-Jun N-terminal kinase (JNK) activity. Inhibits telomerase activity through inhibition of HSP90, a chaperone required for the assembly and activation of telomerase in human cells (6). It is ~10-fold more potent than herbimycin A. Specifically, the geldanamycin fluorescent probe may be used for detection of cell surface Hsp90, may be used in fluorescence polarization assays, and characterizations of geldanamycin drug-target interactions.

1. Whitesell L., et al. (1994) Proc. Natl. Acad. Sci. USA 91:8324.
2. Neckers L. (2002) Trends Mol. Med. 8: S55.
3. Mabjeesh N.J., et al. (2002) Cancer Res. 62: 2478.
4. Chavany C., et al. 1996) Amer. Society Biochem Mol Bio. 9: 4974-4977.
5. Villa R., et al. (2003) Carcinogenesis. 24(5): 851-9.
6. Yamaki H., Iguchi-Ariga S.M., and Ariga H. (1989) J Antibiot (Tokyo). 42(4): 604-10.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Support products are guaranteed for 6 months from date of receipt.

Publications for FITC-geldanamycin (NB610-81561) (0)

There are no publications for FITC-geldanamycin (NB610-81561).
By submitting your publication information earn gift cards and discounts for future purchases.

Reviews for FITC-geldanamycin (NB610-81561) (0)

There are no reviews for FITC-geldanamycin (NB610-81561). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for FITC-geldanamycin (NB610-81561) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional FITC-geldanamycin Products

Research Areas for FITC-geldanamycin (NB610-81561)

Find related products by research area.

Blogs on FITC-geldanamycin

There are no specific blogs for FITC-geldanamycin, but you can read our latest blog posts.

Contact Information

Product PDFs

Review this Product

Be the first to review our FITC-geldanamycin and receive a gift card or discount.